Entrectinib (Rozlytrek)


 CADTH recommends that Rozlytrek be reimbursed by public drug plans for the treatment of adults with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without known acquired resistance mutation if certain conditions are met.
 should only to treat patients who previously failed on all standard treatments their current tumour site and will able tolerate treatment.
 as single-agent therapy not initiated in primary CNS tumours those received prior an NTRK inhibitor.